Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides

A technology of composition and factors, applied in the preparation and treatment of subjects suffering from bleeding episodes, drugs for treating subjects with bleeding episodes, preventing their episodes, and promoting the formation of blood coagulation in subjects, which can solve difficult and unsuccessful treatments And other issues

Inactive Publication Date: 2004-12-22
NOVO NORDISK AS
View PDF14 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Once a subject develops these serious complications, a cascade of events involving many cytokines and an inflammatory response begins, making any treatment very difficult and unfortunately often unsuccessful

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
  • Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
  • Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0186] Compound preparation:

[0187] The human purified factor VIIa suitable for use in the present invention is preferably obtained by DNA recombinant technology, for example according to Hagen et al., Proc. Natl. Acad. Sci. USA 83 : 2412-2416, 1986, or prepared as described in European Patent No. 200,421 (ZymoGenetics, Inc.).

[0188] Factor VII is also available according to Broze and Majerus, J.Biol.Chem.255 (4): 1242-1247, 1980 and Hedner and Kisiel, J. Clin. Invest. 71 : 1836-1841, produced by the method described in 1983. These methods yield Factor VII without detectable amounts of other coagulation factors. Even more purified Factor VII preparations can be obtained by including an additional gel filtration as a final purification step. Factor VII can then be converted to activated factor FVIIa by known methods, for example by several different plasma proteins, eg Factor XIIa, IX or Xa. In addition, according to Bjoern et al. (Research Disclosure, 269 , Septem...

Embodiment approach 2

[0242] Embodiment 2: The composition of aspect 1, wherein said Factor VII or Factor VII-related polypeptide is a Factor VII-related polypeptide.

Embodiment approach 3

[0243] Embodiment 3: The composition of Aspect 1, wherein Factor Vila is human Factor Vila.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to compositions comprising factor VII or factor VII-related polypeptides and factor XI or factor XI-related polypeptides, and their use for the treatment of bleeding episodes.

Description

technical field [0001] The present invention relates to pharmaceutical compositions comprising Factor VII or Factor VII-related polypeptides and Factor XI or Factor XI-related polypeptides. The present invention also relates to the combination of factor VII or factor VII-related polypeptide and factor XI or factor XI-related polypeptide in the preparation of a medicament for treating a subject suffering from bleeding episodes, or preventing their onset. The invention also relates to methods of treating bleeding episodes in a subject and methods of promoting coagulation in a subject. The invention also relates to kits containing these compounds. Background technique [0002] Hemostasis is initiated by the formation of a complex between tissue factor (TF) exposed to circulating blood following vessel wall injury and circulating FVIIa present in amounts corresponding to approximately 1% of the total FVII protein mass. This complex anchors to TF-bearing cells and activates FX ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00A61K38/48A61P7/04
CPCA61K38/4846A61P7/04A61K2300/00A61K38/16
Inventor 拉斯马斯·罗杰克杰尔
Owner NOVO NORDISK AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com